Abstract Objectives This study investigated the fertilizing potential of leuprolide acetate in infertile patients with endometriosis (EMS). Methods This study included 116 patients with the EMS infertility, who were randomly divided into the control group and the leuprolide acetate group. Patients of the former only underwent laparoscopic surgery, while those in the latter were additionally administered leuprolide acetate subcutaneous injections. The serum luteinizing hormone, estradiol, follicle-stimulating hormone, and cancer antigen 125 (CA125) levels of all subjects were measured using commercial ELISA kits. And Kaplan-Meier analysis was conducted to show the cumulative pregnancy rate within one year of follow-up. Furthermore, the recurrence rate and incidence of adverse events after treatment were analyzed. Results The serum luteinizing hormone, estradiol, and follicle-stimulating hormone levels were statistically insignificant in both groups before treatment (p > 0.05). However, their levels were typically suppressed after treatment, with a greater decrease observed in the leuprolide acetate group than in the control group (p < 0.05). The pregnancy rate was significantly higher in the leuprolide acetate group (62.07 %) than in the control group (20.69 %) after treatment. Additionally, the former exhibited a higher pregnancy rate in the one-year follow-up (log-rank p < 0.001). It also had a significantly lower recurrence rate and CA125 level compared to the control group (p < 0.05). Conclusions Treatment involving leuprolide acetate after laparoscopic surgery can improve the chance of pregnancy and reduce the endometriosis recurrence rate in infertile endometriosis patients.
Jiang et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: